Search

everythinglearnresearchcommunity

for

Search:↓

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Anorexia Nervosa and Bulimia Nervosa are complex eating disorders with increasing incidence among young females, significant morbidity, and varying mortality rates, requiring more research for better treatment.

Prolactin may be important for skin growth and immune function.

Finasteride doesn't affect hormone levels in normal men.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

The nafarelin test can reliably distinguish between gonadotropin deficiency and delayed puberty in teenage boys.

The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.

GnRH analogue can help diagnose ovarian causes of high testosterone in postmenopausal women when scans don't show the cause.

GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.

Metformin can start ovulation and may lower 17P response in PCOS, but six months is too short to improve hair growth or change body fat distribution.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Both finasteride and GnRH agonist treatments reduced hair growth in women with idiopathic hirsutism, but GnRH agonist was more effective.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Transgender treatment includes hormones and surgery, but long-term effects are unknown and counseling is needed.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.

Women with regular menstrual cycles and PCOS have linked kisspeptin and LH hormone patterns, unlike those with irregular cycles.

The research found that polycystic ovary syndrome (PCOS) has two distinct types, with one having more severe hormone and insulin issues.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

Some medicines can reduce excessive hair growth in women, but more research is needed to compare treatments and consider side effects.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

Hormonal treatments can improve acne, but they come with potential side effects and risks.

Hormonal treatment is effective for women with acne not helped by usual treatments, especially if they have hormonal imbalances.

For women with moderate to severe unwanted hair growth or acne, birth control pills are the first choice, with other medications like cyproterone, spironolactone, flutamide, or finasteride as alternatives, and permanent hair removal should be done with electrolysis or laser.

Different anti-androgen medications can help treat excessive hair growth, but the right choice depends on accurate diagnosis.

Most patients improved with oral contraceptives, but some needed additional treatment.

The conclusion is that removing both ovaries is the best treatment for excess male hormones in postmenopausal women, with medication as another option, and managing insulin resistance is important for diagnosis and treatment.

Certain brain hormones and chemicals are linked to the development of Polycystic Ovary Syndrome.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.